Course of Face-to-face Interactions in Adults With Autism
Launched by UMC UTRECHT · Apr 10, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how adults with autism and those without (called neurotypical adults) make eye contact during different types of conversations. Researchers want to understand how the type of conversation affects eye contact, like how often it happens and for how long. They are also interested in how eye contact affects stress levels—whether it makes people feel more relaxed, more stressed, or doesn’t change their stress at all. Additionally, the study will compare how people with autism respond to eye contact from others versus how they make eye contact themselves.
To participate in this trial, you need to be an adult aged 18 to 65 and be either neurotypical or diagnosed with autism using a recognized system. You should be able to understand instructions and be motivated to join the research. However, if you struggle with the Dutch language, have a history of using drugs or alcohol during the study, or if you are experiencing severe mental health issues, you may not be able to participate. If you decide to join, you can expect to take part in discussions and activities that will help researchers learn more about eye contact and its effects on stress for adults with autism and those without.
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • Neurotypical adults and adults with an ASD, determined according to an internationally recognized classification system.
- • Able to understand the instructions.
- • Motivation to participate in research.
- • Exclusion criteria
- • No good command of the Dutch language.
- • Use of alcohol and/or recreational drugs during the research.
- • Mentally too unstable to participate in the research.
- • Familiarity with treatment in the VGZ.
About Umc Utrecht
UMC Utrecht is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research and high-quality patient care. As a prominent sponsor of clinical trials, UMC Utrecht leverages its extensive expertise in translational medicine and collaboration with various stakeholders to advance medical knowledge and improve therapeutic outcomes. The institution emphasizes ethical conduct and rigorous scientific standards, ensuring that all research activities contribute meaningfully to the global healthcare landscape. Through its robust clinical trial infrastructure, UMC Utrecht plays a vital role in facilitating the development of new treatments and enhancing patient wellbeing.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Deventer, Overijssel, Netherlands
Patients applied
Trial Officials
Nynke Boonstra, Professor
Study Chair
UMC Utrecht
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported